Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Registration Number
- NCT01952392
- Lead Sponsor
- AstraZeneca
- Brief Summary
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Detailed Description
AReMIS (Antiplatelet and Recurrent Myocardial Infarction Study) To compare the relative risk of new myocardial infarction (recurrent myocardial infarction or 'rMI') in patients with a history of acute coronary syndrome ('ACS': unstable angina or myocardial infarction), using ticagrelor, clopidogrel or prasugrel (if applicable) or none of these treatments, where aspirin is considered a covariate.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4992
Patients aged 18 years or more, both genders, with an acute coronary syndrome (ACS), agreed to participate and able to respond to an interview in French and/or providing the details of an alternative replier (proxy) if necessary.
No Exclusion Criteria.
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Medical information At baseline visit History of coagulation and vascular disorders History of cerebrovascular accidents Cardiovascular risk factors
Drug exposure Past Past exposure: more than a week (7 days) before the recurrent MI and until the ACS index. Exposure to clopidogrel, ticagrelor, prasugrel, aspirin, other antiplatelet drugs.
- Secondary Outcome Measures
Name Time Method Other medical events of interest During follow-up (up to 12 months) rMI, stroke, bleeding, death
Trial Locations
- Locations (1)
Research Site
🇫🇷Paris, France